Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phase 2 and 3 trials.

Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y.

Mod Rheumatol. 2019 Feb 20:1-23. doi: 10.1080/14397595.2019.1583711. [Epub ahead of print]

PMID:
30784354
2.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Feb 2. pii: annrheumdis-2018-214280. doi: 10.1136/annrheumdis-2018-214280. [Epub ahead of print]

PMID:
30712015
3.

Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C.

Siegel SAR, Winthrop KL, Ehst BD, Ortega Loayza A.

Br J Dermatol. 2018 Nov 20. doi: 10.1111/bjd.17444. [Epub ahead of print] No abstract available.

PMID:
30460766
4.

Advancing Translational Science for Pulmonary NTM Infections: A Roadmap for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2018 Nov 14. doi: 10.1164/rccm.201807-1273PP. [Epub ahead of print]

PMID:
30428263
5.

Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response.

Skopelja-Gardner S, Theprungsirikul J, Meagher RE, Beliveau CM, Bradley KE, Avery M, Henkle E, Siegel S, Gifford AH, Winthrop KL, Rigby WFC.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801891. doi: 10.1183/13993003.01891-2018. Print 2019 Feb. No abstract available.

PMID:
30385530
6.

Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis.

Park JK, Lee YJ, Bitoun S, Winthrop KL, Choi Y, Lee EB, Mariette X.

Ann Rheum Dis. 2019 Feb;78(2):282-284. doi: 10.1136/annrheumdis-2018-214025. Epub 2018 Oct 8. No abstract available.

PMID:
30297326
7.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

PMID:
30295434
8.

Specificity of QuantiFERON-TB Plus, a New-Generation Interferon Gamma Release Assay.

Siegel SAR, Cavanaugh M, Ku JH, Kawamura LM, Winthrop KL.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e00629-18. doi: 10.1128/JCM.00629-18. Print 2018 Dec.

PMID:
30232132
9.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL.

J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.

10.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Sep 14. doi: 10.1164/rccm.201807-1318OC. [Epub ahead of print]

PMID:
30216086
11.

Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection.

Liu VX, Winthrop KL, Lu Y, Sharifi H, Nasiri HU, Ruoss SJ.

Ann Am Thorac Soc. 2018 Oct;15(10):1169-1176. doi: 10.1513/AnnalsATS.201804-245OC.

PMID:
30213194
12.

Treatment of Mycobacterium abscessus Complex.

Strnad L, Winthrop KL.

Semin Respir Crit Care Med. 2018 Jun;39(3):362-376. doi: 10.1055/s-0038-1651494. Epub 2018 Aug 2. Review.

PMID:
30071551
13.

Mycobacterial Disease: Evolving Concepts.

Flume PA, Winthrop KL.

Semin Respir Crit Care Med. 2018 Jun;39(3):269. doi: 10.1055/s-0038-1660862. Epub 2018 Aug 2. No abstract available.

PMID:
30071542
14.

Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.

Henkle E, Chan B, Curtis JR, Aksamit TR, Daley CL, Winthrop KL.

Chest. 2018 Dec;154(6):1311-1320. doi: 10.1016/j.chest.2018.07.014. Epub 2018 Jul 25.

PMID:
30055168
15.

US Patient-Centered Research Priorities and Roadmap for Bronchiectasis.

Henkle E, Aksamit TR, Daley CL, Griffith DE, O'Donnell AE, Quittner AL, Malanga E, Prieto D, Leitman A, Winthrop KL.

Chest. 2018 Nov;154(5):1016-1023. doi: 10.1016/j.chest.2018.06.032. Epub 2018 Jul 5.

PMID:
29981718
16.

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration.

Jones MM, Winthrop KL, Nelson SD, Duvall SL, Patterson OV, Nechodom KE, Findley KE, Radonovich LJ Jr, Samore MH, Fennelly KP.

PLoS One. 2018 Jun 13;13(6):e0197976. doi: 10.1371/journal.pone.0197976. eCollection 2018.

17.

Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.

Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG.

JAMA Ophthalmol. 2018 Aug 1;136(8):849-856. doi: 10.1001/jamaophthalmol.2018.1171.

PMID:
29879277
18.

Multicenter study of QuantiFERON®-TB Gold Plus in patients with active tuberculosis.

Horne DJ, Jones BE, Kamada A, Fukushima K, Winthrop KL, Siegel SAR, Kovacs A, Anthony P, Meekin KA, Bhat S, Kerndt P, Chang A, Koelle DM, Narita M.

Int J Tuberc Lung Dis. 2018 Jun 1;22(6):617-621. doi: 10.5588/ijtld.17.0721.

PMID:
29862944
19.

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.

Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C.

Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131.

PMID:
29850873
20.

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.

Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB.

Ann Rheum Dis. 2018 Jun;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222. Epub 2018 Mar 23.

21.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar. No abstract available.

PMID:
29567726
22.

Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question.

Winthrop KL, Baddley JW.

Ann Rheum Dis. 2018 May;77(5):631-633. doi: 10.1136/annrheumdis-2017-212588. Epub 2018 Feb 19. No abstract available.

PMID:
29459427
23.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Review.

PMID:
29447987
24.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

PMID:
29371384
25.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

PMID:
29371383
26.

The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis.

Metersky ML, Aksamit TR, Barker A, Choate R, Daley CL, Daniels LA, DiMango A, Eden E, Griffith D, Johnson M, Knowles M, O'Donnell AE, Olivier K, Salathe M, Thomashow B, Tino G, Turino G, Winthrop KL, Mannino D.

Ann Am Thorac Soc. 2018 Mar;15(3):365-370. doi: 10.1513/AnnalsATS.201706-426OC.

PMID:
29345970
27.

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.

Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H.

J Am Acad Dermatol. 2018 Jun;78(6):1149-1155.e1. doi: 10.1016/j.jaad.2017.09.076. Epub 2018 Mar 2.

PMID:
29080806
28.

Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, Oregon, USA, 2007-2012.

Henkle E, Hedberg K, Schafer SD, Winthrop KL.

Emerg Infect Dis. 2017 Oct;23(10):1627-1630. doi: 10.3201/eid2310.170845.

29.

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E.

Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6.

30.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.

Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.

31.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

PMID:
28811201
32.

Herpes zoster in psoriasis patients treated with tofacitinib.

Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, Gupta P, Ito K, Tan H, Kaur M, Egeberg A, Mallbris L, Valdez H.

J Am Acad Dermatol. 2017 Aug;77(2):302-309. doi: 10.1016/j.jaad.2017.03.023.

PMID:
28711084
33.

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.

Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16.

PMID:
28600810
34.

Pharmacotherapy: Biosimilar switching - "To set a form upon desired change".

Kay J, Winthrop KL.

Nat Rev Rheumatol. 2017 Jul;13(7):391-392. doi: 10.1038/nrrheum.2017.79. Epub 2017 Jun 1. No abstract available.

PMID:
28569266
35.

Frequency of untreated hypogammaglobulinemia in bronchiectasis.

Ruffner MA, Aksamit TR, Thomashow B, Choate R, DiMango A, Turino GM, O'Donnell AE, Johnson MM, Olivier KN, Fennelly K, Daley CL, Winthrop KL, Metersky ML, Salathe MA, Knowles MR, Daniels MLA, Noone PG, Tino G, Griffith DE, Sullivan KE.

Ann Allergy Asthma Immunol. 2017 Jul;119(1):83-85. doi: 10.1016/j.anai.2017.04.020. Epub 2017 May 20. No abstract available.

PMID:
28539185
36.

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8.

37.

Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, DiMango A, Eden E, Fennelly K, Griffith DE, Johnson M, Knowles MR, Leitman A, Leitman P, Malanga E, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Prieto D, Salathe M, Thomashow B, Tino G, Turino G, Wisclenny S, Winthrop KL.

Chest. 2017 Dec;152(6):1120-1127. doi: 10.1016/j.chest.2017.04.167. Epub 2017 May 5.

38.

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.

Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB.

Ann Rheum Dis. 2017 Sep;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128. Epub 2017 May 3.

PMID:
28468794
39.

Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation.

Henkle E, Novosad SA, Shafer S, Hedberg K, Siegel SAR, Ku J, Varley C, Prevots DR, Marras TK, Winthrop KL.

Ann Am Thorac Soc. 2017 Jul;14(7):1120-1128. doi: 10.1513/AnnalsATS.201610-801OC.

40.

Mortality after Respiratory Isolation of Nontuberculous Mycobacteria. A Comparison of Patients Who Did and Did Not Meet Disease Criteria.

Novosad SA, Henkle E, Schafer S, Hedberg K, Ku J, Siegel SAR, Choi D, Slatore CG, Winthrop KL.

Ann Am Thorac Soc. 2017 Jul;14(7):1112-1119. doi: 10.1513/AnnalsATS.201610-800OC.

41.

The emerging safety profile of JAK inhibitors in rheumatic disease.

Winthrop KL.

Nat Rev Rheumatol. 2017 May;13(5):320. doi: 10.1038/nrrheum.2017.51. Epub 2017 Mar 31. No abstract available.

PMID:
28360424
42.

The emerging safety profile of JAK inhibitors in rheumatic disease.

Winthrop KL.

Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2. Review. Erratum in: Nat Rev Rheumatol. 2017 May;13(5):320.

PMID:
28250461
43.

Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.

Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, Winthrop KL, Baddley JW.

J Rheumatol. 2017 May;44(5):565-570. doi: 10.3899/jrheum.160983. Epub 2017 Mar 1.

PMID:
28250142
44.

Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013.

Marras TK, Campitelli MA, Lu H, Chung H, Brode SK, Marchand-Austin A, Winthrop KL, Gershon AS, Kwong JC, Jamieson FB.

Emerg Infect Dis. 2017 Mar;23(3):468-476. doi: 10.3201/eid2303.161927.

45.

Disseminated Nontuberculous Mycobacteria in HIV-Infected Patients, Oregon, USA, 2007-2012.

Varley CD, Ku JH, Henkle E, Schafer SD, Winthrop KL.

Emerg Infect Dis. 2017 Mar;23(3):533-535. doi: 10.3201/eid2303.161708.

46.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.

Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

47.

Pathogens and antibiotic sensitivities in endophthalmitis.

Slean GR, Shorstein NH, Liu L, Paschal JF, Winthrop KL, Herrinton LJ.

Clin Exp Ophthalmol. 2017 Jul;45(5):481-488. doi: 10.1111/ceo.12910. Epub 2017 Jan 31.

48.

On the Reportability of Nontuberculous Mycobacterial Disease to Public Health Authorities.

Winthrop KL, Henkle E, Walker A, Cassidy M, Hedberg K, Schafer S.

Ann Am Thorac Soc. 2017 Mar;14(3):314-317. doi: 10.1513/AnnalsATS.201610-802PS.

PMID:
27997817
49.

Infection and Malignancy in Rheumatic Diseases.

Winthrop KL, Calabrese LH.

Rheum Dis Clin North Am. 2017 Feb;43(1):xiii-xiv. doi: 10.1016/j.rdc.2016.10.001. No abstract available.

PMID:
27890178
50.

Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.

Friedman MA, Winthrop KL.

Rheum Dis Clin North Am. 2017 Feb;43(1):1-13. doi: 10.1016/j.rdc.2016.09.003. Epub 2016 Oct 22. Review.

PMID:
27890167

Supplemental Content

Loading ...
Support Center